We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TEVIMBRA BeOne Medicines AUS Pty Ltd
Product name
TEVIMBRA
Sponsor
Accepted date
Jul-2025
Active ingredients
tislelizumab
Proposed indication
Tevimbra (tislelizumab) is used together with other chemotherapy medicines to treat people with extensive-stage small cell lung cancer (SCLC). It is proposed to be given as the first treatment after diagnosis.
Application type
C (new indication)
Publication date
Jul-2025